218 related articles for article (PubMed ID: 17974567)
1. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Alfano RW; Leppla SH; Liu S; Bugge TH; Ortiz JM; Lairmore TC; Duesbery NS; Mitchell IC; Nwariaku F; Frankel AE
Mol Cancer Ther; 2010 Jan; 9(1):190-201. PubMed ID: 20053778
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Alfano RW; Leppla SH; Liu S; Bugge TH; Herlyn M; Smalley KS; Bromberg-White JL; Duesbery NS; Frankel AE
Mol Cancer Ther; 2008 May; 7(5):1218-26. PubMed ID: 18483309
[TBL] [Abstract][Full Text] [Related]
5. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Schafer JM; Peters DE; Morley T; Liu S; Molinolo AA; Leppla SH; Bugge TH
PLoS One; 2011; 6(5):e20532. PubMed ID: 21655226
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
Alfano RW; Leppla SH; Liu S; Bugge TH; Duesbery NS; Frankel AE
Cell Cycle; 2008 Mar; 7(6):745-9. PubMed ID: 18245947
[TBL] [Abstract][Full Text] [Related]
7. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Abi-Habib RJ; Urieto JO; Liu S; Leppla SH; Duesbery NS; Frankel AE
Mol Cancer Ther; 2005 Sep; 4(9):1303-10. PubMed ID: 16170021
[TBL] [Abstract][Full Text] [Related]
8. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA; Liu S; Bugge TH; Torres JB; Mosley M; Hopkins SL; Allen PD; Berridge G; Vendrell I; Fischer R; Kersemans V; Smart S; Leppla SH; Cornelissen B
J Nucl Med; 2019 Oct; 60(10):1474-1482. PubMed ID: 30954944
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.
Alfano RW; Leppla SH; Liu S; Bugge TH; Meininger CJ; Lairmore TC; Mulne AF; Davis SH; Duesbery NS; Frankel AE
Mol Cancer Res; 2009 Apr; 7(4):452-61. PubMed ID: 19372576
[TBL] [Abstract][Full Text] [Related]
10. An anthrax toxin variant with an improved activity in tumor targeting.
Wein AN; Peters DE; Valivullah Z; Hoover BJ; Tatineni A; Ma Q; Fattah R; Bugge TH; Leppla SH; Liu S
Sci Rep; 2015 Nov; 5():16267. PubMed ID: 26584669
[TBL] [Abstract][Full Text] [Related]
11. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth.
Rogers MS; Christensen KA; Birsner AE; Short SM; Wigelsworth DJ; Collier RJ; D'Amato RJ
Cancer Res; 2007 Oct; 67(20):9980-5. PubMed ID: 17942931
[TBL] [Abstract][Full Text] [Related]
12. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.
Zai X; Zhang J; Liu J; Liu J; Li L; Yin Y; Fu L; Xu J; Chen W
Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26927174
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Liu S; Netzel-Arnett S; Birkedal-Hansen H; Leppla SH
Cancer Res; 2000 Nov; 60(21):6061-7. PubMed ID: 11085528
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
16. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
[TBL] [Abstract][Full Text] [Related]
17. Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
Rozanov DV; Golubkov VS; Strongin AY
Int J Biochem Cell Biol; 2005 Jan; 37(1):142-54. PubMed ID: 15381157
[TBL] [Abstract][Full Text] [Related]
18. Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality.
Mendenhall MA; Liu S; Portley MK; O'Mard D; Fattah R; Szabo R; Bugge TH; Khillan JS; Leppla SH; Moayeri M
Nat Microbiol; 2020 Dec; 5(12):1464-1471. PubMed ID: 32895527
[TBL] [Abstract][Full Text] [Related]
19. Constitutive MEK1 activation rescues anthrax lethal toxin-induced vascular effects in vivo.
Bolcome RE; Chan J
Infect Immun; 2010 Dec; 78(12):5043-53. PubMed ID: 20855511
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model.
Li N; Zheng D; Wei X; Jin Z; Zhang C; Li K
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1131-44. PubMed ID: 22402599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]